Olympus to buy BioProtect in $270M urology-oncology deal

Olympus said on May 26 it signed a definitive agreement to acquire BioProtect for about $270 million, adding the Israeli company’s biodegradable Balloon Spacer system to its urology and oncology portfolio. BioProtect’s device is used during prostate cancer radiation therapy to create temporary space between the prostate and nearby tissues, with the goal of reducing treatment-related toxicity. Olympus said the deal is expected to close by the end of the second quarter of calendar 2026, subject to customary conditions. BioProtect reported about $14.5 million in 2025 revenue, has 130 employees, and says its spacer has been used in more than 11,000 procedures worldwide since its 2023 commercial launch. The device received FDA 510(k) clearance in August 2023. (olympusamerica.com)

Why it matters: For veterinary professionals, this is another sign that large medtech companies are still buying into procedure-adjacent technologies that improve safety, workflow, and quality of life rather than only core imaging or surgical platforms. While this transaction is in human prostate cancer care, the strategic logic will feel familiar to veterinary teams: Olympus is using M&A to deepen its position in specialty care pathways, especially in urology and minimally invasive intervention. That can matter downstream for innovation trends, capital allocation, and the kinds of translational device concepts that may eventually influence veterinary oncology and interventional practice. (olympusamerica.com)

What to watch: Watch for closing confirmation by late June 2026, and for how quickly Olympus moves to scale BioProtect’s spacer technology through its global urology and oncology channels. (olympusamerica.com)